Bruker BRKR Bsi Biospin — Cost Of Segment Revenue

Similar metrics at other companies

BDXBioPharma Systems — Segment Cost of Products and Services Sold as a Percent of Revenues

53.6%+0.4pp

BDXBioPharma Systems — Cost of products sold

$316M+3.3%

IFFHealth & Biosciences — Cost of Product and Service Sold

$327M+9.7%

IFFHealth & Biosciences — Cost of Sales

$327M+9.7%

BDXBioPharma Systems — Segment Operating Income (Loss) as a Percent of Revenues

38.1%-0.8pp

RVTYLife Sciences — Segment Cost of Revenue

$131.57M+10.3%

Questions, answered.

What is Bruker's bsi biospin — cost of segment revenue?

Bruker (BRKR) reported bsi biospin — cost of segment revenue of $102.7M in Q1 2026.

How has Bruker's bsi biospin — cost of segment revenue changed year-over-year?

Bruker's bsi biospin — cost of segment revenue decreased by 6.4% year-over-year, from $109.7M to $102.7M.

What is the long-term trend for Bruker's bsi biospin — cost of segment revenue?

Over 3 years (2022 to 2025), Bruker's bsi biospin — cost of segment revenue has grown at a 13.3% compound annual growth rate (CAGR), from $320.6M to $465.9M.

What does bsi biospin — cost of segment revenue mean?

This represents the direct costs associated with producing and delivering the goods and services sold by the BioSpin segment. It includes raw materials, direct labor, and manufacturing overhead directly attributable to the segment's operations. Monitoring this helps evaluate the segment's production efficiency and gross margin potential.